What Msd Pharma Hungary does

MSD Pharma Hungary Korlátolt Felelősségű Társaság (MSD Hungary Kft.) is the Hungarian operating subsidiary of Merck & Co., Inc. (NYSE: MRK), a global biopharmaceutical company. Established in Hungary around 1990 and headquartered at Lechner Ödön fasor 10/B, Budapest, the company employs approximately 200 people, of whom roughly 100 work in research and development. MSD Hungary operates across six core therapeutic areas — oncology, vaccines, hospital infections (anti-infectives), HIV, immunology, and diabetes — and maintains a separate MSD Animal Health business unit. The company runs nearly 70 clinical trials at approximately 250 investigation sites with around 400 actively treated patients, supported by annual clinical research investment of HUF 3 billion since 2020 (HUF 45 billion cumulative 2010-2024), of which roughly one-third is delivered as free investigational medicine to patients. The portfolio is anchored by MSD's global immuno-oncology platform built on Nobel Prize-winning science and includes a neoantigen-based personalized cancer therapy co-developed with Moderna that is currently in Phase 3 for lung cancer.

The business model centers on pharmaceutical product sales (prescription medicines and vaccines) distributed through regulated wholesale channels and a regional distribution center established in Hungary in 2014 that serves 14 European countries. Pricing is set through national reimbursement schemes and tender processes governed by Hungary's National Health Insurance Fund (NEAK). Go-to-market is enterprise-led, with field sales representatives and clinical research teams targeting hospitals, academic centers (notably Semmelweis University and Hungary's four medical universities), and government health bodies. Patient-facing digital channels — including hpvdoktor.hu, hpvoltas.com, diabeteszinfo.hu, and clinical trial referral portals — supplement traditional sales outreach. A distinctive in-country capability is MSD Hungary's data research program that analyzes NEAK and EESZT national health databases to generate real-world epidemiological evidence, with findings (e.g., the HULC study) cited by the OECD-European Commission in shaping EU oncology policy. The company also benefits from MSD's Global Health Innovation Fund (USD 600 million since 2010), which has deployed USD 25 million+ into Budapest-based Turbine AI for AI-driven clinical trial matching and therapy target identification.

Name

Msd Pharma Hungary

Legal name

MSD Pharma Hungary Korlátolt Felelősségű Társaság

Website

https://msd.hu

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

101–250 employees

Short description

MSD Pharma Hungary is the Hungarian subsidiary of Merck & Co., Inc., operating across oncology, vaccines, HIV, immunology, hospital infections, and diabetes, serving Hungarian patients, hospitals, and government health bodies through pharmaceutical sales and a substantial clinical research program.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

akta.pro secondary industries

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG)

Keywords

• Prescription pharmaceuticals
• Vaccine products
• Clinical research services
• Oncology therapies
• Immuno-oncology treatments

Headquarters

HQ city

Budapest

HQ country

Hungary

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: MSD generates revenue through the sale of innovative prescription medicines and vaccines across therapeutic areas including oncology, vaccines, HIV, immunology, and hospital infections. Revenue is derived from direct sales to healthcare providers, hospitals, and pharmacies in Hungary and the broader Central European region.
2. Vaccine Sales: Sale of vaccines for children and adults covering diseases including MMR, chickenpox, hepatitis B, rotavirus, HPV, and pneumococcal disease.
3. Clinical Trial Delivery: MSD funds clinical trials in Hungary, providing free investigational medicines to patients. Approximately one-third of annual trial investment (HUF ~1 billion) is provided in the form of medicine, relieving the National Health Insurance Fund of spending nearly HUF 1 billion. This drives prescriber relationships and future product adoption.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

MSD Pharma Hungary Kft. develops, manufactures, and commercializes innovative prescription medicines and vaccines across six therapeutic areas: oncology (including immuno-oncology and personalized neoantigen-based therapies), vaccines, hospital anti-infectives, HIV, immunology, and diabetes. The company also operates a regional distribution center serving 14 European countries and runs one of Hungary's largest clinical trial programs with approximately 70 active trials, 250 investigation sites, and 400 actively treated patients.

Product overview

MSD Pharma Hungary Kft. is the Hungarian subsidiary of Merck & Co., Inc. (operating internationally as MSD), a global biopharmaceutical company present in Hungary for more than 30 years. The company operates a multi-platform portfolio anchored by six core therapeutic areas — oncology, vaccines, hospital infections (anti-infectives), HIV, immunology, and diabetes — supplemented by dedicated patient education portals including hpvdoktor.hu and hpvoltas.com (for HPV awareness), diabeteszinfo.hu/msddiabetesz.hu (for diabetes), and a clinical trials information service for patients and physicians. The company also maintains a distinct MSD Animal Health business unit. MSD Hungary has approximately 200 employees, with roughly 100 in R&D, and conducts around 70 clinical trials at 250 sites with approximately 400 actively treated patients. Its proprietary data research program generates real-world epidemiological evidence from Hungarian health databases, contributing to policy-making and clinical practice. The company is also supported by the MSD Global Health Innovation Fund, which has invested in digital health companies including Hungary's Turbine AI.

Differentiator

Problem solved

Functional benefit

Brands

• MSD Animal Health: Animal health division of MSD providing veterinary pharmaceutical products
• MSD for Mothers
• MSD Global Health Innovation Fund

Products and services

• Oncology Therapeutics (Onkológia)
• Vaccines Portfolio (Védőoltások)
• HIV Antiretroviral Therapies (HIV)
• Immunology Biologics (Immunológia)
• Hospital Anti-Infectives (Kórházi fertőzések)
• Clinical Trials Program
• MSD Hungary Data Research Program
• MSD Animal Health (MSD Állategészségügy)

Quantifiable outcome

• Clinical trials provide free medicines to Hungarian patients, relieving the National Health Insurance Fund of nearly HUF 1 billion annually in drug costs.
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

• Semmelweis UniversityflagshipStrategic or Co-development Partner · 1 May 2025MSD and Semmelweis University signed a comprehensive strategic cooperation agreement in May 2025 covering joint clinical trials (30 ongoing/planned in cardiology, oncology, pulmonology, immunology, and pediatrics), epidemiological research, AI applications, data-driven healthcare solutions, and training programs. The university's Phase I accredited center is a key pillar for MSD's early-phase clinical trials. The partnership aims to improve access to innovative treatments for Hungarian patients and develop a chronic disease database for Hungary.
• ModernacoreStrategic or Co-development Partner · 1 January 2018MSD is developing neoantigen-based personalized cancer medicine in collaboration with Moderna. This individualized therapy was first tested in 2018 and is currently in Phase 3 clinical trial for lung cancer. The therapy is 100% tailored to each patient's genetic information.
• AccentureminorStrategic or Co-development PartnerMSD and Accenture jointly launched the capABILITY in Action program for the recruitment of neurodivergent talent, collaborating with Rangam Consultants Inc. Accenture provides digital and cloud technology expertise alongside MSD's commitment to diverse workforce building.
• Rangam Consultants Inc.minorChannel Partner/ Reseller/ DistributorRangam is a minority-owned, women-owned diverse company recognized as a Disability Owned Business Enterprise (DOBE) by Disability:IN. It runs the SourceAbled program to attract, recruit, and retain neurodivergent talent, placing candidates at partner companies including MSD.
• Society for Women EngineersminorStrategic or Co-development PartnerMSD partnered with Society for Women Engineers (SWE) nonprofit organization and iReLaunch team to create the Re-invent program, providing six-month return scholarships for experienced professionals returning after career breaks.
• iReLaunchminorStrategic or Co-development PartneriReLaunch collaborates with MSD on the Re-invent return-to-work program, offering professional internships for adults re-entering the workforce after career breaks.
• Disability:INminorOthersDisability:IN is a non-profit organization that provides disability certification (Disability Owned Business Enterprise - DOBE) to businesses owned by persons with disabilities. MSD engages with Disability:IN for its supplier diversity program and won the Top Company Award in July 2021.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Sanofi: Comparable in vaccines, immunology (rheumatology, IBD, dermatology), and hospital specialty care. Sanofi's Hungarian operations and clinical research footprint align with MSD Hungary's mix of therapeutic areas and enterprise hospital sales model.
• AstraZeneca: Directly comparable in oncology (immuno-oncology, targeted therapies) and respiratory/infectious disease, with comparable clinical trial investment and Central European market presence. AZ's portfolio and pipeline depth in oncology is a direct competitor to MSD's IO franchise.
• Pfizer: Global biopharmaceutical major with overlapping therapeutic areas (oncology, vaccines, infectious diseases, immunology) and a comparable Central European / Hungarian commercial and clinical trial presence. Directly comparable in product portfolio breadth, sales-led GTM to hospitals and physicians, and clinical trial investment model.
• AbbVie: Directly comparable in immunology (rheumatology, IBD, psoriasis) and oncology, with a similar specialty-biologics and hospital-facing commercial approach. AbbVie's Hungarian operations overlap with MSD's immunology franchise and clinical research model.
• Novartis: Directly comparable in oncology and immunology, with a similar mix of innovative prescription medicines, hospital-facing sales, and clinical trial activity in Hungary. Both companies operate multi-therapeutic-area portfolios with strong biologics and specialty-pharma positioning.
• Roche: Closest peer in oncology, immunology, and hospital anti-infectives, with a comparable pipeline-driven, hospital-focused commercial model. Roche is a global leader in immuno-oncology and personalized healthcare, directly overlapping MSD's core therapeutic franchises and clinical research approach.
• GSK: Direct peer in vaccines (including pediatric and adult immunization, HPV) and a relevant peer in HIV and immunology. GSK's established vaccine portfolio and Hungarian commercial operations are directly comparable to MSD Hungary's vaccine therapeutic area and immunization offerings.
• Bristol-Myers Squibb: Direct peer in immuno-oncology and hematology, with a pipeline and commercial model centered on innovative oncology biologics. BMS's Hungarian presence and clinical trial activity in oncology directly overlap with MSD Hungary's core oncology franchise.
• Eli Lilly: Direct peer as a major innovative pharma with oncology, immunology, and cardiometabolic/diabetes franchises — overlapping MSD's oncology, immunology, and diabetes therapeutic areas. Lilly's growing Hungarian clinical and commercial presence makes it a relevant comparator in diabetes and oncology.
• Johnson & Johnson (Janssen): Comparable as a diversified pharma major with strong oncology, immunology, and infectious disease franchises, and a similar local operating model in Hungary covering sales, clinical research, and real-world evidence. Janssen's hospital-facing specialty pharma approach closely mirrors MSD's GTM motion.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/user/noidolgok
• LinkedInlinkedin.com/company/msd-magyarorszag

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Msd Pharma Hungary